VIVUS (VVUS) Reaches New 1-Year Low at $0.60
Shares of VIVUS, Inc. (NASDAQ:VVUS) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $0.60 and last traded at $0.61, with a volume of 346500 shares. The stock had previously closed at $0.62.
Separately, ValuEngine downgraded VIVUS from a “buy” rating to a “hold” rating in a report on Friday, September 1st.
The stock has a market capitalization of $65.38, a price-to-earnings ratio of 1.82 and a beta of 0.77. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09.
VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.07. The company had revenue of $15.19 million during the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. VIVUS’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.09) EPS. sell-side analysts predict that VIVUS, Inc. will post -0.32 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of VVUS. Bank of New York Mellon Corp increased its position in shares of VIVUS by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 3,694 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of VIVUS by 84.8% during the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 68,200 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of VIVUS during the second quarter worth about $100,000. AJO LP acquired a new stake in shares of VIVUS during the second quarter worth about $3,329,000. Finally, Northern Trust Corp increased its position in shares of VIVUS by 16.8% during the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 39,473 shares in the last quarter. Institutional investors and hedge funds own 31.35% of the company’s stock.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.